Furthermore, treatment of MetS patients with glucagon-like peptide-1 receptor agonists (GLP-1RA) over a six-month period led to a significant reduction in serum GPHB5 levels after 3 to 6 months of therapy. This evidence concerns the gene GPHB5 and metabolic syndrome.